Essential thrombocythemia (ET) is a clonal bone marrow disease, characterized by increased production of platelets along with other clinical and bone marrow findings. Most patients with ET will have a somatic mutation in one of the known gene locations of JAK2, CALR , or MPL that can upregulate the JAK-STAT pathway. MPL mutation is present in 5% of cases with the most common mutations being W515L and W515K. In this report we describe 2 cases of patients with clinical and laboratory picture of ET. One patient carried MPLY252H mutation which is previously unreported in the adult population but has been shown to be a gain-of-function mutation. The other patient carried MPL F126fs mutation which is not known to be of clinical importance and has not been previously reported.
Introduction
Essential thrombocythemia (ET) is a clonal bone marrow disease, characterized by increased production of platelets. Most patients with ET will have a somatic mutation in Janus Kinase 2 (JAK2), Calreticulin (CALR), or myeloproliferative leukemia virus oncogene (MPL) with subsequent upregulation of the JAK-STAT pathway. JAK2 V617F activating mutation is present in 50-60% of ET cases, CALR mutation is present in 20-25% of cases, while MPL mutation is present in 5% of cases. Patients who lack all three mutations are usually called triple negative. The most common mutations in MPL are W515L and W515K. 1 Other mutations were also reported such as S505N, W515A and W515R. We hereby report 2 cases of patients with clinical and laboratory picture of ET who carried 2 mutations that are previously unreported in the adult population.
Case Report #1
A 55-year-old female with a past medical history of hypertension, osteoarthritis, neuropathy, and hyperlipidemia presented in consultation for thrombocytosis. She has had thrombocytosis for 8 years prior to presentation. Her laboratory exam showed a platelet count of 558k, white blood cell counts of 9.2k, and hemoglobin of 12.9 gm. She reported having occasional headaches and blurry vision, but was otherwise asymptomatic. Bone marrow biopsy showed mildly hypercellular bone marrow (70%) showing trilineage hematopoiesis with mildly increased megakaryocytes. She had adequate reticuloendothelial iron, with no ringed sideroblasts. There was no fibrosis on reticulin stain. No evidence of causes of secondary thrombocytosis was found. Molecular studies showed MPLY252H mutation. Other variants found were EP300, MAP3K7, NTRK1, and YY1AP1.
Case Report #2
A 50-year-old female with a past medical history of diabetes, rheumatoid arthritis, and COPD was referred for thrombocytosis. Further review of laboratory data revealed that her platelet count has been elevated for 4 years prior to her referral. Platelet counts had been ranging from 518-600k. Patient has been asymptomatic and denied any history of thrombotic event. Patient declined bone marrow biopsy so molecular studies were sent from peripheral blood. Results revealed multiple abnormalities. MPL F126fs*5 mutation was detected. Other variants detected included CSF1R, ERBB4, GPR124, KIT, MUTYH, NFE2L2, PIM1, PTPN6, and RNF43. Patient was prescribed Aspirin 81 mg and has been asymptomatic with stable counts after 1 year of follow up.
Discussion and Conclusions
ET is a clonal disease characterized by marked thrombocytosis, prominent large to giant megakaryocytes in bone marrow, and absence of other identifiable causes of thrombocytosis. World Health Organization (WHO) diagnostic criteria includes absence of other clonal bone marrow disorders such as chronic myeloid leukemia and other myeloproliferative neoplasms. The demonstration of clonal markers favors the diagnosis. JAK2, CALR and MPL mutations are the most common. Subsequently the JAK-STAT pathway gets upregulated with further stimulation to cell growth and hematopoiesis. Some of the triple negative cases will have an unusual mutation in JAK2, CALR or MPL on whole gene sequencing. 2 Other mutations in different genes such as ASXL1, TET2, and CBL have been reported in patients with MPN. These can exist with other more common gene mutations and are helpful to establish clonality.
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brane domain is encoded for by exon 10. Exon 1 encodes for signal peptide. 3 The gene encodes for a 635 amino acid transmembrane domain (CD 110). Binding of thrombopoietin to the extracellular domain for MPL leads to dimerization of the receptor and activation of the JAK-STAT pathway. Figure 1 illustrates the structure of human MPL receptor. Disruption of the juxtamembrane region of the thrombopoietin receptor MPL leads to receptor activation in the absence of receptor binding by thrombopoietin. 4 Mutations have been reported in the MPL gene. The MPL W515L mutation has been linked to ET. Transplanting bone marrow cells that express this mutation into mice leads to marked thrombocytosis and splenomegaly, as well as other features associated with MPN. 5 The MPL W515K mutation was discovered several months after MPL W515L, and was shown to be linked to the clinical picture of myeloproliferative neoplasms. 1 Beer et al. performed an analysis of molecular data from a large retrospective cohort of unselected patients with ET and Primary myelofibrosis (PMF). The entire MPL coding region in 18 patients with ET and 2 patients with PMF was sequenced. No mutations were found outside exon 10 in this study. Subsequently, MPL exon 10 in granulocyte DNA from 200 patients was sequenced. Of these, 88 had ET and 112 had 6 MPL W515A and MPL W515R mutations are rare, but they are thought to function like MPL W515K and L. Given the extremely low mutation rate, the clinical significance is not confirmed. 7 Other mutations described are A506T, L510P, and A519T. The clinical significance of these mutations is still unclear. 8 MPL S505N can occur of somatic origin in sporadic cases of ET, but has also been reported along with other MPL mutations in cases with hereditary thrombocythemia (HT). In such cases it is a germline mutation that is inherited in an autosomal dominant pattern. 9 MPL S505N was found to be associated with an increased risk of thrombosis and subsequently splenomegaly and bone marrow fibrosis. 10 Further mutations associated with HT include MPL K39N and MPL P106L. MPL K39N is a polymorphism reported in African Americans. Screening of more than 400 patients and controls revealed that approximately 7% of African Americans are heterozygous for this polymorphism and that patients affected had a significantly higher platelets count than controls without the polymorphism. 11 MPL P106L is another mutation that was associated with familial thrombocytosis. It was discovered in an Arab family when two siblings presented with thrombocytosis. Molecular studies in a sample of 213 people revealed that the prevalence of this mutation is 3.3% in this cohort of unrelated individuals of Arabic descent. The control group of 193 healthy German individuals had no mutation detected. 12 The clinical outcome of individuals with these 2 mutations (MPL K39N and MPL P106L) is still unknown. Other germline mutations that are felt to be associated with HT are MPL V285E and MPL R321W. These are 2 activating germline mutations in exon 6 of MPL identified in 2016 in cases initially diagnosed as ET (R321W) and PMF (V285E). 13 MPL T119I, MPL S204F, MPL S204P, and MPL E230G were reported in 2016. All of these mutations lead to constitutive activation of JAK-STAT signaling indicating that they are gain of function mutations . 13 Interestingly, all these mutations are outside of exon 10. The same report identified a new somatic mutation MPL Y591D in exon 12 in a patient who was initially diagnosed with triple negative ET. This patient, however, developed JAK2 V617F mutation at 5.5 years follow-up. appeared to be gain of function mutations via in vitro studies .14 Table 1 summarizes the mutations reported in MPL gene. [13] [14] [15] [16] [17] The MPL Y252H mutation was first described in 2011 in a three-year-old African American female with a JAK2 mutation-negative ET. Exposing bone marrow cells from this patient to thrombopoietin lead to generation of megakaryocyte colonies in vitro. BaF3 cells with the mutation were found to have increased thrombopoietin mediated cell growth and increased cell survival upon cytokine withdrawal. 15 The MPL Y252H mutation in our case has not been reported in adults before. Based on the work of Lambert et al, this mutation was shown to be a gain of function mutation in the extracellular domain of MPL. 15 
Our second case documents the first clinical case report of a patient with MPL F126fs. This is a frame shift mutation that results in a change in the amino acid sequence of the MPL protein beginning at amino acid 126 of total of 635. This is expected to result in a premature truncation of the functional protein leading to loss of functional domains, which would lead to loss of function. It is interesting that our case documents the occurrence of a clinical picture consistent with ET in a patient with this mutation.
